Friday, October 28, 2011 6:07:20 PM
I think we both know that the real price today(if your bought through the financing) was closer to .77/share(3shares(2share+1option)for the price of 2(1.15x2=2.30/3=.77)). I'm sure as a director, Philip Coelho had easy access to that.
Or, if you bought today in the open market, you could have bought all you wanted for 1.08 or lower,(the low), assuming it doesn't go lower still. "Everyone" of course knows that these things(involving warrants) tend to price lower in the open market than the face issuance price(which again, only makes sense, considering dilution via increased shares and warrants).
Either way,(but particularly in the case of the financing), the discount is very significant.
As far as the "half a brain part", if that's true, assuming any of us had one(half a brain), why would any of us, you and I included, accumulate any before this event?
I know I did because I didn't pay enough attention to the financing pattern. I'm not sure why you did, since you apparently anticipated this event.
No, I'm not aware of any ultra small biotechs which have been able to finance without issuing warrants(though I haven't studied the issue).
But the fact that CPRX's CEO had a large stock position and wasn't likely to issue warrants(particularly since CPRX hadn't to date) was part of their appeal.
Bottom line: I have no problem acknowledging the liabilities of companies I'm willing to invest in. CPRX's addition of warrants certainly is one.
In addition, purchasing before this financing was a mistake on my part, and I think that director demonstrated at least "half a brain" by selling 71% of his position(217k shares) when he did. I just wish I had paid a little more attention to a move like that.
Hopefully, I will in the future.
Regards,
bw
Recent CPRX News
- Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024 • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 • GlobeNewswire Inc. • 04/22/2024 12:00:00 PM
- Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day • GlobeNewswire Inc. • 03/28/2024 12:03:00 PM
- Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium • GlobeNewswire Inc. • 03/27/2024 12:03:00 PM
- Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD) • GlobeNewswire Inc. • 03/13/2024 11:55:00 AM
- Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference • GlobeNewswire Inc. • 03/05/2024 01:03:00 PM
- Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/28/2024 11:03:23 PM
- Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE • GlobeNewswire Inc. • 02/27/2024 01:03:00 PM
- Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology • GlobeNewswire Inc. • 02/21/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:01:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:01:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:00:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:00:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:00:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:00:37 PM
- Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024 • GlobeNewswire Inc. • 02/14/2024 01:03:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 10:15:01 PM
- Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering • GlobeNewswire Inc. • 01/09/2024 09:05:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 10:23:31 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/05/2024 10:15:42 PM
- Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock • GlobeNewswire Inc. • 01/05/2024 01:02:06 PM
- Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 01/04/2024 09:49:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 10:18:58 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM